MedTrace Logo

A Registry of Treatment Adherence for Patients With Schizophrenia

NCT00283517 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2046

Last updated 2010-04-27

No results posted yet for this study

Summary

The purpose of the study is to assess demographic, treatment, and outcome data in schizophrenia patients receiving treatment with long-acting injectable, tablet, or liquid formulations of first generation (conventional) or second generation (atypical) antipsychotic medications.

Conditions

Interventions

DRUG

antipsychotics

as prescribed

Sponsors & Collaborators

  • Janssen-Cilag, S.A.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag S.A. (formerly Janssen Sp) Clinical Trial · Janssen-Cilag, S.A.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-09-30
Completion
2006-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00283517 on ClinicalTrials.gov